Keyphrases
Natural Killer Cells
93%
Engager
75%
Tumor
30%
PD-1 Expression
25%
Transplantation
25%
Lung Cancer
25%
TEM8
25%
Low Density
25%
Mesothelin
25%
Antitumor Activity
25%
Tumor Stroma
25%
NK Cell Cytotoxicity
25%
Prostate-specific Antigen
25%
Prostate Cancer
25%
Interleukin-15 (IL-15)
17%
Programmed Death-ligand 1 (PD-L1)
16%
Cytokine Production
12%
Non-small Cell Lung Cancer (NSCLC)
9%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
9%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
9%
Current Therapies
8%
CD16
8%
Cell Killing
8%
Tumor Infiltration
7%
Cell Proliferation
7%
Tumor Cells
7%
Tumor Microenvironment
7%
Healthy Individuals
6%
Early-stage Lung Cancer
6%
Pembrolizumab
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
ScFv
6%
Immunosuppressive Environment
6%
Tumor Stromal Cells
5%
Stromal Cells
5%
Fibroblasts
5%
Endothelial Cells
5%
Solid Tumors
5%
Inflammatory Cytokines
5%
Immunology and Microbiology
Natural Killer Cell
100%
Cytotoxicity
35%
Stroma
25%
Antineoplastic Activity
25%
Mesothelin
25%
Prostate Specific Membrane Antigen
25%
Cytokine Production
13%
CD16
12%
Interleukin 15
11%
Immunosuppressive Drug
10%
Cell Killing
9%
Prostate
9%
Degranulation
8%
Tumor Cell
6%
Cell Function
6%
Pembrolizumab
5%
Programmed Death 1 Ligand 1
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Natural Killer Cell Response
5%
Mass Cytometry
5%
Antibody-Dependent Cell-Mediated Cytotoxicity
5%
CD14
5%
Mononuclear Cell
5%
Preclinical Study
5%
Fc Receptor
5%
Myeloid
5%
Medicine and Dentistry
Natural Killer Cell
75%
Cytotoxicity
31%
Lung Cancer
25%
Mesothelin
25%
Non Small Cell Lung Cancer
25%
Prostate Specific Membrane Antigen
25%
Prostate Cancer
25%
Neoplasm
9%
Castration Resistant Prostate Cancer
9%
Cytokine Production
7%
Immunosuppressive Drug
6%
Diseases
6%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Programmed Death 1 Ligand 1
5%
Pembrolizumab
5%
